Bruton Tyrosine Kinase Inhibitors in Patients with Multiple Sclerosis

Ryan Haumschild, PharmD, MS, MBA, leads a discussion around the epidemiology of multiple sclerosis.

The pathophysiology and treatment of active and inactive MS are explored.

An expert panel discusses cost burden associated with the treatment of MS.

Key opinion leaders highlight the MS treatment landscape.

Frontline treatment options and the benefits of early intervention of MS are illustrated.

Dr Haumschild leads a discussion surrounding patient and provider collaboration to avoid clinical inertia in MS treatment pathways.

The panelists provide insights into the decision-making process behind switching MS treatment strategies due to lacking or failed therapies.

BTK inhibitor implementation for MS treatment is explored.

The panel expands on the role of BTK inhibitors in the MS treatment landscape.

A discussion surrounding clinical trials in multiple sclerosis is led by Dr Haumschild.

A comprehensive look into MS treatment objectives is provided.

With their final thoughts, the panelists emphasize patient-centered care is at the forefront of critical MS treatment considerations for providers.